[Special Stock] "Boehringer Technology Return" Yuhan Yanghaeng Weakness

As of 9:20 AM on the 7th, Yuhan Corporation's stock price on the Korea Exchange was recorded at 119,100 KRW, down 4.57% from the previous closing price. This appears to be due to the news of the return of rights for a substance that was licensed out six years ago.

On this day, Yuhan Corporation announced that it received a notice on the 6th from global big pharma Boehringer Ingelheim regarding the termination of the contract and return of rights related to the substance (BI 3006337) being developed as a treatment for metabolic dysfunction-associated steatohepatitis (MASH).

This substance was licensed out in July 2019 with a contract amount and milestone payments totaling up to 870 million USD.

A Yuhan Corporation representative stated, "There is no financial loss as the 50 million USD received from the contract and milestone technology fees from the licensing out are not subject to return," and "based on the potential to address unmet medical needs of patients and positive safety results in clinical trials, we are considering continuing the development of this substance."

This content was produced with the assistance of AI translation services.